Next-generation sequencing in non-muscle-invasive bladder cancer-a step towards personalized medicine for a superficial bladder tumor.
作者信息
Butterfield Andrew, Gupta Sumati
机构信息
Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
出版信息
Transl Androl Urol. 2017 Dec;6(6):1198-1202. doi: 10.21037/tau.2017.11.27.
Abstract
摘要
相似文献
1
Next-generation sequencing in non-muscle-invasive bladder cancer-a step towards personalized medicine for a superficial bladder tumor.非肌层浸润性膀胱癌的下一代测序——迈向浅表性膀胱肿瘤个性化医疗的一步。
Transl Androl Urol. 2017 Dec;6(6):1198-1202. doi: 10.21037/tau.2017.11.27.
2
Advances in risk stratification of bladder cancer to guide personalized medicine.膀胱癌风险分层以指导个性化医疗的进展。
F1000Res. 2018 Jul 25;7. doi: 10.12688/f1000research.14903.1. eCollection 2018.
3
New strategies in muscle-invasive bladder cancer: on the road to personalized medicine.肌层浸润性膀胱癌的新策略：迈向个体化医学之路。
Clin Cancer Res. 2011 May 1;17(9):2608-12. doi: 10.1158/1078-0432.CCR-10-2770. Epub 2011 Mar 17.
4
Interest of next-generation sequencing in BCG-treated high-risk bladder cancer.下一代测序在卡介苗治疗的高危膀胱癌中的应用价值
Prog Urol. 2018 May;28(6):344-350. doi: 10.1016/j.purol.2018.03.008. Epub 2018 Apr 17.
5
Next-Generation Sequencing: The Translational Medicine Approach from "Bench to Bedside to Population".下一代测序技术：从“实验室到床边再到人群”的转化医学方法
Medicines (Basel). 2016 Jun 2;3(2):14. doi: 10.3390/medicines3020014.
6
New Roadmaps for Non-muscle-invasive Bladder Cancer With Unfavorable Prognosis.预后不良的非肌层浸润性膀胱癌新路线图
Front Chem. 2020 Jul 31;8:600. doi: 10.3389/fchem.2020.00600. eCollection 2020.
7
Toward personalized management in bladder cancer: the promise of novel molecular taxonomy.迈向膀胱癌的个性化管理：新型分子分类法的前景
Virchows Arch. 2017 Aug;471(2):271-280. doi: 10.1007/s00428-017-2119-x. Epub 2017 Apr 21.
8
Next Generation Sequencing (NGS): A Revolutionary Technology in Pharmacogenomics and Personalized Medicine in Cancer.下一代测序（NGS）：癌症中药物基因组学和个性化医学的革命性技术。
Adv Exp Med Biol. 2019;1168:9-30. doi: 10.1007/978-3-030-24100-1_2.
9
Management and prognosis of transitional cell carcinoma superficial recurrence in muscle-invasive bladder cancer after bladder preservation.膀胱保留术后肌层浸润性膀胱癌浅表复发的管理与预后
Eur Urol. 2003 Aug;44(2):222-5; discussoion 225. doi: 10.1016/s0302-2838(03)00258-6.
10
Transurethral resection of the bladder tumour (TURBT) for non-muscle invasive bladder cancer: basic skills.经尿道膀胱肿瘤切除术（TURBT）治疗非肌肉浸润性膀胱癌：基本技能。
Int J Urol. 2010 Aug;17(8):698-9. doi: 10.1111/j.1442-2042.2010.02556.x.
引用本文的文献
1
Predictive Molecular Biomarkers of Bladder Cancer Identified by Next-Generation Sequencing-Preliminary Data.通过下一代测序确定的膀胱癌预测性分子生物标志物——初步数据
J Clin Med. 2024 Dec 17;13(24):7701. doi: 10.3390/jcm13247701.
2
Individual patient risk of progression of urinary bladder papillary tumors estimated from biomarkers at initial transurethral resection of bladder tumor.基于初始经尿道膀胱肿瘤切除术时的生物标志物估计的尿路上皮性膀胱乳头状肿瘤患者进展的个体风险。
J Cancer Res Clin Oncol. 2019 Jul;145(7):1709-1718. doi: 10.1007/s00432-019-02923-1. Epub 2019 Apr 27.
3
Circulating Tumor Cells Identify Patients with Super-High-Risk Non-Muscle-Invasive Bladder Cancer: Updated Outcome Analysis of a Prospective Single-Center Trial.循环肿瘤细胞可识别超高危非肌层浸润性膀胱癌患者：一项前瞻性单中心试验的更新结果分析。
Oncologist. 2019 May;24(5):612-616. doi: 10.1634/theoncologist.2018-0784. Epub 2019 Apr 3.
本文引用的文献
1
Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer.肌层浸润性膀胱癌的综合分子特征分析
Cell. 2017 Oct 19;171(3):540-556.e25. doi: 10.1016/j.cell.2017.09.007. Epub 2017 Oct 5.
2
Comparison of the EORTC tables and the EAU categories for risk stratification of patients with nonmuscle-invasive bladder cancer.欧洲癌症研究与治疗组织（EORTC）表格与欧洲泌尿外科学会（EAU）非肌层浸润性膀胱癌患者风险分层类别之比较。
Urol Oncol. 2018 Jan;36(1):8.e17-8.e24. doi: 10.1016/j.urolonc.2017.08.027. Epub 2017 Sep 23.
3
Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets.非肌肉浸润性膀胱癌的下一代测序揭示了潜在的生物标志物和合理的治疗靶点。
Eur Urol. 2017 Dec;72(6):952-959. doi: 10.1016/j.eururo.2017.05.032. Epub 2017 Jun 3.
4
Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.BGJ398（一种成纤维细胞生长因子受体1-3激酶抑制剂）在携带成纤维细胞生长因子受体基因改变的晚期实体瘤患者中的评估：一项全球I期剂量递增和剂量扩展研究的结果
J Clin Oncol. 2017 Jan 10;35(2):157-165. doi: 10.1200/JCO.2016.67.2048. Epub 2016 Nov 21.
5
EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.EAU 指南：非肌层浸润性膀胱尿路上皮癌：2016 年更新版。
Eur Urol. 2017 Mar;71(3):447-461. doi: 10.1016/j.eururo.2016.05.041. Epub 2016 Jun 17.
6
Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma.早期尿路上皮癌的综合转录组分析。
Cancer Cell. 2016 Jul 11;30(1):27-42. doi: 10.1016/j.ccell.2016.05.004. Epub 2016 Jun 16.
7
Clarification of Bladder Cancer Disease States Following Treatment of Patients with Intravesical BCG.膀胱内卡介苗治疗患者后膀胱癌疾病状态的阐明
Bladder Cancer. 2015 Mar 30;1(1):29-30. doi: 10.3233/BLC-159002.
8
Low Molecular Weight Fucoidan Inhibits Tumor Angiogenesis through Downregulation of HIF-1/VEGF Signaling under Hypoxia.低分子量岩藻依聚糖在低氧条件下通过下调HIF-1/VEGF信号通路抑制肿瘤血管生成。
Mar Drugs. 2015 Jul 17;13(7):4436-51. doi: 10.3390/md13074436.
9
A Molecular Pathologic Framework for Risk Stratification of Stage T1 Urothelial Carcinoma.T1 期尿路上皮癌风险分层的分子病理框架。
Eur Urol. 2015 Nov;68(5):824-32; discussion 835-6. doi: 10.1016/j.eururo.2015.02.021. Epub 2015 Mar 11.
10
Next-generation RNA sequencing of archival formalin-fixed paraffin-embedded urothelial bladder cancer.存档福尔马林固定石蜡包埋尿路上皮膀胱癌的下一代 RNA 测序。
Eur Urol. 2014 Dec;66(6):982-6. doi: 10.1016/j.eururo.2014.07.045. Epub 2014 Sep 6.
Zotero 插件